• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFR14A filed by INmune Bio Inc.

    5/9/25 4:05:05 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INMB alert in real time by email
    DEFR14A 1 ea0241465-defr14a_inmune.htm REVISED DEFINITIVE PROXY STATEMENT

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    (Amendment No. 1)

     

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934, as Amended

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant  ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
       
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ☒ Definitive Proxy Statement
       
    ☐ Definitive Additional Materials
       
    ☐ Soliciting Material under Section 240.14a-12

     

    INmune Bio Inc.

    (Name of Registrant as Specified in its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒ No fee required
       
    ☐ Fee paid previously with preliminary materials:
       
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

    INmune Bio Inc.

     

    Dear Stockholder:

     

    On May 7, 2025, we dismissed Marcum LLP as our independent registered public accounting firm, not as a result of any disagreement on any matter of accounting principles or practices, financial statement disclosure, or audit scope or procedure and appointed CBIZ CPAs P.C. (“CBIZ CPAs”). We are enclosing herewith Amendment No. 1 to Schedule 14A (“Amendment No. 1”), filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 9, 2025, which amends Proposal No. 2 (“Proposal No. 2”) of our original definitive proxy statement on Schedule 14A, as filed with the SEC on April 21, 2025 (the “Original Definitive Proxy Statement”), as supplemented by the proxy supplement to our Original Definitive Proxy Statement (together, with the Original Definitive Proxy Statement, the “Definitive Proxy Statement”), as filed with the SEC on April 25, 2025, to reflect the substitution of CBIZ CPAs, to submit their appointment for stockholder ratification, to make certain technical amendments related to this change, and to revise the date of the 2025 annual meeting of stockholders (the “Meeting”) from May 28, 2025 to June 10, 2025. The record date of April 14, 2025, remains unchanged.

     

    All votes received on proposals for consideration at the Meeting, including Proposal No. 2, prior to the filing and mailing of this Amendment No. 1, shall continue to be counted. Therefore, if you have already voted your shares, you do not need to vote again unless you would like to change or revoke your prior vote. If you have already voted and wish to change your vote, you may revoke your original proxy and submit a new proxy by completing, dating, signing and returning the enclosed proxy, or submitting a new proxy through the internet or by telephone.

     

    If you are a stockholder in “street” or “nominee” name, you may revoke your voting instructions and submit new voting instructions by informing the bank, broker or other nominee in accordance with that entity’s procedures for revoking your voting instructions and issuing new instructions. For additional information regarding revoking your proxy, please refer to page 5 of the Original Definitive Proxy Statement.

     

    Your vote is important to us. We appreciate your attention to this matter.

     

    Sincerely,

     

    /s/ David Moss  
    David Moss  
    Chief Financial Officer and Secretary  
    May 9, 2025  

     

     

     

     

    IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF THE STOCKHOLDERS OF INMUNE BIO INC. TO BE HELD ON:

     

    TUESDAY, JUNE 10, 2025, AT 10:00 A.M. EASTERN TIME

     

    VIA THE VIRTUAL MEETING PORTAL AT:

     

    www.virtualshareholdermeeting.com/INMB2025

     

    THE NOTICE, OUR DEFINITIVE PROXY STATEMENT, THIS AMENDMENT NO. 1 AND OUR ANNUAL REPORT ARE AVAILABLE ONLINE AT:

     

    www.proxyvote.com and https://www.inmunebio.com/index.php/en/investors/filings

     

     

     

     

    EXPLANATORY NOTE

     

    Effective May 7, 2025, the Audit Committee of the Board of Directors of INmune Bio Inc. (the “Audit Committee” and the “Company” or “INmune,” respectively) notified Marcum LLP that Marcum LLP was dismissed as the Company’s independent registered public accounting firm, not as a result of any disagreement on any matter of accounting principles or practices, financial statement disclosure, or audit scope or procedure. As of May 7, 2025, the Audit Committee appointed CBIZ CPAs P.C. (“CBIZ CPAs”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, effective immediately. The Company filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (the “SEC”) reporting this change on May 7, 2025.

     

    This Amendment No. 1 to our Definitive Proxy Statement (as defined below) on Schedule 14A (“Amendment No. 1”) is being filed with the SEC to amend Proposal No. 2 (“Proposal No. 2”) of our definitive proxy statement on Schedule 14A, as filed with the SEC on April 21, 2025 (the “Original Definitive Proxy Statement”), as supplemented by the proxy supplement to our Original Definitive Proxy Statement (together, with the Original Definitive Proxy Statement, the “Definitive Proxy Statement”), as filed with the SEC on April 25, 2025, to reflect the substitution of CBIZ CPAs, to submit their appointment for stockholder ratification, to make certain technical amendments related to this change, and to revise the date of the 2025 annual meeting of stockholders (the “Meeting”) from May 28, 2025 to June 10, 2025.

     

    All votes received on proposals for consideration at the Meeting, including Proposal No. 2, prior to the filing and mailing of this Amendment No. 1, shall continue to be counted. Therefore, if you have already voted your shares, you do not need to vote again unless you would like to change or revoke your prior vote. If you have already voted and wish to change your vote, you may revoke your original proxy and submit a new proxy by completing, dating, signing and returning the enclosed proxy, or submitting a new proxy through the internet or by telephone.

     

    If you are a stockholder in “street” or “nominee” name, you may revoke your voting instructions and submit new voting instructions by informing the bank, broker or other nominee in accordance with that entity’s procedures for revoking your voting instructions and issuing new instructions. For additional information regarding revoking your proxy, please refer to page 5 of the Original Definitive Proxy Statement.

     

    This Amendment No. 1 amends only those items set forth or described below, and all other items in the Definitive Proxy Statement are incorporated herein by reference without changes, including the record date of April 14, 2025, which remains unchanged.

     

    1

     

     

    CHANGES TO DEFINITIVE PROXY STATEMENT

     

    1.All references to Marcum LLP in the “Notice of Annual Meeting of Stockholders” and the Definitive Proxy Statement are amended to read “CBIZ CPAs P.C.” or “CBIZ CPAs” as appropriate or unless otherwise noted.

     

    2.All references to the Meeting date of May 28, 2025 shall be amended and replaced with June 10, 2025.

     

    3.The Audit Committee Report is amended in its entirety to read as follows:

     

    AUDIT COMMITTEE REPORT 

     

    The audit committee has reviewed and discussed with management our audited financial statements for the fiscal year ended December 31, 2024, which were audited by Marcum LLP, our independent registered public accounting firm for the fiscal year ended December 31, 2024. The audit committee discussed with Marcum LLP the matters required to be discussed pursuant to Public Company Accounting Oversight Board (“PCAOB”) Auditing Standard 1301. The audit committee received the written disclosures and letter from Marcum LLP required by applicable requirements of the PCAOB regarding the independent registered public accounting firm’s communications with the audit committee concerning independence, and discussed with the independent registered public accounting firm the independent registered public accounting firm’s independence. The audit committee also considered whether the provision of services other than the audit of our financial statements for the fiscal year ended December 31, 2024 were compatible with maintaining Marcum LLP’s independence.

     

    The audit committee has selected CBIZ CPAs as our independent auditor for the fiscal year ended December 31, 2025, and is seeking ratification of the selection by our stockholders.

     

      Respectfully submitted by the audit committee,
      Messrs. Schroeder, Juda and Allen

     

    4.Proposal No. 2 in the Definitive Proxy Statement is amended in its entirety to read as follows:

     

    2

     

     

    PROPOSAL NO. 2 — RATIFICATION OF THE APPOINTMENT OF INDEPENDENT
    REGISTERED PUBLIC ACCOUNTING FIRM

     

    Proposal

     

    We are asking our stockholders to ratify the appointment by the audit committee (the “audit committee”) of our Board of Directors of CBIZ CPAs P.C. (“CBIZ CPAs”), to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2025. The audit committee has further directed that management submit the selection of our independent registered public accounting firm for ratification by the stockholders at the Meeting. Although our Bylaws do not require that our stockholders approve the appointment of our independent registered public accounting firm, the audit committee is submitting the selection of CBIZ CPAs to our stockholders for ratification at the Meeting as a matter of good corporate practice and because we value our stockholders’ views on our independent registered public accounting firm.

     

    If the appointment of CBIZ CPAs is not ratified, the audit committee will evaluate the basis for the stockholders’ vote when determining whether to continue the firm’s engagement, but may ultimately determine to continue the engagement of the firm or another audit firm without re-submitting the matter to stockholders. Even if the appointment of CBIZ CPAs is ratified, the audit committee may terminate the engagement of the firm and direct the appointment of another independent auditor at any time during the year if it determines that such an appointment would be in the best interests of our Company and our stockholders.

     

    Representatives of CBIZ CPAs are not expected to attend the Meeting.

     

    Change in Independent Registered Public Accounting Firm

     

    On November 1, 2024, CBIZ CPAs acquired the attest business of Marcum LLP. On May 7, 2025, with the approval of the audit committee, the Company dismissed Marcum LLP as our independent registered public accounting firm. Previously, Marcum LLP served as our independent registered public accounting firm from August 5, 2018 to May 7, 2025, and reported on our financial statements for the years ended December 31, 2018, 2019, 2020, 2021, 2022, 2023 and 2024.

     

    The audit report of Marcum LLP on the Company’s consolidated financial statements as of and for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope, or accounting principles, except that the report included an explanatory paragraph relating to substantial doubt about the Company’s ability to continue as a going concern.

     

    During the fiscal years ended December 31, 2024 and 2023 and through May 7, 2025, there were no (1) “disagreements” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Marcum LLP on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum LLP, would have caused Marcum LLP to make reference to the subject matter of the disagreement in their reports on the financial statements for such years, or (2) “reportable events” (as described in Item 304(a)(1)(v) of Regulation S-K).

     

    We provided Marcum LLP with a copy of the above disclosures and requested that Marcum LLP furnish us with a letter addressed to the SEC stating whether it agrees with the statements made above and, if it does not agree, the respects in which it does not agree. A copy of Marcum LLP’s letter, dated May 7, 2025, was attached as Exhibit 16.1 to our Current Report on Form 8-K filed with the SEC on May 7, 2025.

     

    3

     

     

    Approval of Appointment of CBIZ CPAs P.C. as Our New Independent Registered Public Accounting Firm

     

    On May 7, 2025, with the approval of the Company’s audit committee, CBIZ CPAs was engaged as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.

     

    During the fiscal years ended December 31, 2024 and 2023, and through May 7, 2025, neither the Company nor anyone on its behalf consulted with CBIZ CPAs regarding (1) the application of accounting principles to a specified transaction, completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that CBIZ CPAs concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (2) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

     

    Fees

     

    The aggregate fees billed to us for professional services by Marcum LLP rendered for the years ended December 31, 2024 and 2023, are set forth in the table below:

     

    Fee Category  For the
    Year Ended
    December 31,
    2024
       For the
    Year Ended
    December 31,
    2023
     
    Audit fees(1)  $418,261   $342,058 
    Audit-related fees(2)   —    — 
    Tax fees(3)   23,304    22,402 
    All other fees(4)   —    — 
    Total fees  $441,565   $364,460 

     

     

    (1)Audit fees consist of fees incurred for professional services rendered for the audit of consolidated financial statements, for reviews of our interim consolidated financial statements included in our quarterly reports on Forms 10-Q and for services that are normally provided in connection with statutory or regulatory filings or engagements. Includes professional services performed for filing of the Company’s registration statement on Form S-3 and for the Company’s equity offerings.

     

    (2)Audit-related fees consist of fees billed for professional services that are reasonably related to the performance of the audit or review of our consolidated financial statements, but are not reported under “Audit fees.”

     

    (3)Tax fees consist of fees billed for professional services relating to tax compliance, tax planning, and tax advice.

     

    (4)All other fees consist of fees billed for all other services.

     

    Audit Committee

     

    The audit committee, among other things, is responsible for:

     

    ●Appointing, approving the compensation of, overseeing the work of, and assessing the independence, qualifications, and performance of the independent auditor;

     

    ●reviewing the internal audit function, including its independence, plans, and budget;

     

    ●approving, in advance, audit and any permissible non-audit services performed by our independent auditor;

     

    ●reviewing our internal controls with the independent auditor, the internal auditor, and management;

     

    4

     

     

    ●reviewing the adequacy of our accounting and financial controls as reported by the independent auditor, the internal auditor, and management;

     

    ●overseeing our financial compliance system; and

     

    ●overseeing our major risk exposures regarding the Company’s accounting and financial reporting policies, the activities of our internal audit function, and information technology.

     

    The Board of Directors has affirmatively determined that each member of the audit committee meets the additional independence criteria applicable to audit committee members under SEC rules and the Nasdaq Stock Market LLC. The Board of Directors has adopted a written charter setting forth the authority and responsibilities of the audit committee. The Board of Directors has affirmatively determined that each member of the audit committee is financially literate, and that all members meet the qualifications of an audit committee financial expert. The audit committee consists of Timothy Schroeder, Scott Juda, J.D., and Marcia Allen. Scott Juda, J.D., is the chairman of the audit committee.

     

    Based on their review, the audit committee recommended to the Board of Directors that the audited financial statements be included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 for filing with the SEC.

     

    Required Stockholder Vote and Recommendation of Our Board of Directors

     

    Approval of our independent registered public accounting firm requires the affirmative vote of a majority of the votes cast at the Meeting, whether in person or by proxy, provided that a quorum is present. An abstention will not be counted for or against the proposal, and therefore will not affect the vote outcome.

     

    OUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE
    “FOR” THE RATIFICATION OF CBIZ CPAs P.C. AS OUR INDEPENDENT REGISTERED ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDED DECEMBER 31, 2025.

     

    5

     

     

     

     

     

     

     

     

     

     

     

    Get the next $INMB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INMB

    DatePrice TargetRatingAnalyst
    7/1/2025$0.60Sector Outperform → Sector Underperform
    Scotiabank
    7/1/2025Buy → Neutral
    BTIG Research
    1/28/2025$23.00Buy
    Rodman & Renshaw
    10/21/2024$20.00Buy
    Alliance Global Partners
    9/27/2024$18.00Outperform
    Raymond James
    8/22/2024$22.00Sector Outperform
    Scotiabank
    6/1/2023$16.00Outperform
    Robert W. Baird
    5/24/2022$14.00 → $7.00Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $INMB
    SEC Filings

    View All

    INmune Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Inmune Bio, Inc. (0001711754) (Filer)

    1/27/26 4:00:38 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    INmune Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Inmune Bio, Inc. (0001711754) (Filer)

    12/23/25 4:00:32 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    INmune Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Inmune Bio, Inc. (0001711754) (Filer)

    12/19/25 4:30:33 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INMB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Moss David J

    4 - Inmune Bio, Inc. (0001711754) (Issuer)

    12/2/25 4:44:20 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Lowdell Mark William

    4 - Inmune Bio, Inc. (0001711754) (Issuer)

    12/2/25 4:43:26 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by INmune Bio Inc.

    4 - Inmune Bio, Inc. (0001711754) (Issuer)

    12/2/25 4:42:26 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INMB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    INmune Bio downgraded by BTIG Research

    BTIG Research downgraded INmune Bio from Buy to Neutral

    7/1/25 8:14:45 AM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    INmune Bio downgraded by Scotiabank with a new price target

    Scotiabank downgraded INmune Bio from Sector Outperform to Sector Underperform and set a new price target of $0.60

    7/1/25 8:14:45 AM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on INmune Bio with a new price target

    Rodman & Renshaw initiated coverage of INmune Bio with a rating of Buy and set a new price target of $23.00

    1/28/25 7:14:13 AM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INMB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Moss David J bought $52,868 worth of shares (10,000 units at $5.29), increasing direct ownership by 0.78% to 1,285,869 units (SEC Form 4)

    4 - Inmune Bio, Inc. (0001711754) (Issuer)

    9/30/24 4:01:02 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Tesi Raymond Joseph bought $98,048 worth of shares (15,380 units at $6.38), increasing direct ownership by 1.00% to 1,554,106 units (SEC Form 4)

    4 - Inmune Bio, Inc. (0001711754) (Issuer)

    9/16/24 8:48:44 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Moss David J bought $49,024 worth of shares (7,690 units at $6.38), increasing direct ownership by 0.61% to 1,275,869 units (SEC Form 4)

    4 - Inmune Bio, Inc. (0001711754) (Issuer)

    9/16/24 8:47:21 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INMB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer's Disease

    Agency Feedback Provides Regulatory Clarity on Enrichment Strategy and Confirms CDR-SB as Sole Primary Endpoint for Registrational Development Boca Raton, FL, Feb. 12, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB) ("INmune Bio" or the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it received the official minutes from its End-of-Phase 2 (Type B) meeting with the U.S. Food and Drug Administration (FDA).  The minutes confirm regulatory alignment on the Company's proposed integrated Phase 2b/3 clinical development strategy for XPro1595 in early Alzheimer's Disease (AD). "The outcome of the End-of-Phase 2 interaction i

    2/12/26 7:00:00 AM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB

    Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), designed to streamline the final approval process and reduce time to market Boca Raton, FL, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) ("INmune" or the "Company"), a clinical-stage inflammation and immunology company, today announced a critical step toward the commercialization of CORDStrom™ for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).  The Company has formally submitted its pre-submission package for CORDStrom with the United Kingdom's Medicines and Healthcare Products Regulatory Agenc

    2/10/26 8:00:00 AM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives

    Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: Dear Fellow Shareholders, As we reflect on 2025, I want to thank you for your continued support of INmune Bio. This past year marked an important period of execution, discipline, and focus as we advanced our mission to develop innovative therapies that address serious neuroinflammatory and immunologic diseases with high unmet needs. 2025 was a pivotal year for our company, highlighted by compelling clinical learnings from XPro™ in our Phase 2 Alzheimer's disease trial and significant progr

    1/27/26 9:25:00 AM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INMB
    Leadership Updates

    Live Leadership Updates

    View All

    INmune Bio Inc. to Join Russell 3000® Index

    Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion

    5/30/24 8:00:00 AM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

    DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the appointment of Dr. Ed Baracchini as chairman of the Company's board of directors. "As a member of the CoImmune board of directors, Dr. Baracchini has provided strong counsel and guidance on many important issues in corporate development and strategy," stated Dr. Charles Nicolette, chief executive officer. "In his new role as chairman, his depth of experience in both biotechnology and fundraising will provide new levels of insight and guidance as we seek to advance our novel pipeline o

    11/15/21 8:00:00 AM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INMB
    Financials

    Live finance-specific insights

    View All

    INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

    BOCA RATON, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2025 and provides a business update. Q3 2025 and Recent Corporate Highlights   CORDStrom™ Platform: Announced successful completion of first two commercial pilot-scale manufacturing runs of CORDStrom™ at CGT Catapult in preparation of regulatory filings to seek approval of CORDStrom™ for recessive dystrophic epidemolysis bullosa (RDEB).CORDStrom™ is on target to file

    10/30/25 4:05:00 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025

    Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 23, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), INmune Bio Inc. (NASDAQ:INMB), a clinical-stage inflammation and immunology company, today announces that it will host a conference call on Thursday, October 30, 2025 at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2025 and to provide a corporate update. Conference Call Information To participate in this event, dial-in approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching an operator. Date: Oct

    10/23/25 7:00:00 AM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

    Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"),  a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, August 7th, 2025 at 4:30pm EDT to discuss results for its quarter ended June 30, 2025 and to provide a corporate update.  Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator. Date: August 7th, 2025 Time: 4:30 PM Eastern Time Particip

    7/31/25 7:00:00 AM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INMB
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Breaking: Stock Acquired at INmune Bio Inc. on Jun 26

    Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

    6/26/24 2:54:12 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $INMB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by INmune Bio Inc.

    SC 13G - Inmune Bio, Inc. (0001711754) (Subject)

    10/25/24 10:15:45 AM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by INmune Bio Inc.

    SC 13G/A - Inmune Bio, Inc. (0001711754) (Subject)

    10/2/24 4:50:56 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by INmune Bio Inc.

    SC 13G - Inmune Bio, Inc. (0001711754) (Subject)

    2/15/23 5:06:34 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care